Company: APXIF
Filing Date: 2025-07-03
Form Type: F-4/A
Source: 0001213900-25-061545
Chunk: 696

Company: APx Acquisition Corp. I
Filing Date: 2025-07-03
Form: F-4/A
Chunk 696
---
IOCERES         |     | 09/1/2023  |     | 9/1/2028   |     | 6.5%     |     | US$      |     |     135,025 |     |    140,466 |     |         — |
| Total Borrowings |     |            |     |            |     |          |     |          |     |   2,510,737 |     |  2,661,008 |     | 1,129,957 |

____________ (*)See Note 1 about the restructuring of intercompany debt with Heritas Ltd. as an element of the BCA.

F-155

Notes to Combined Financial Statements (Amounts in US Dollars, except otherwise indicated) 20.Related parties (cont.) Outstanding balances and transactions with other related parties: CIBIC The Group commercializes its diagnostics services through an exclusive commercialization partnership agreement with CIBIC.

|                   |     | June 30, 
     2024 |     | June 30, 
     2023 |
|:------------------|:----|---------:|:----|---------:|
| Trade receivables |     |   18,056 |     |  297,953 |
| Trade payables    |     |   21,024 |     |   37,830 |

Transactions with CIBIC are as follows:

|                                       |     | Years ended June 30, |     |           |
|                                       |     |                 2024 |     |      2023 |
| Revenue – Heritas Diagnostics         |     |            1,702,559 |     | 1,792,109 |
| Laboratory services provided by CIBIC |     |               58,680 |     |    47,640 |
| IT Services provided by CIBIC         |     |               10,500 |     |         — |

Bioceres S.A. The Group commercializes its genetic sequencing services to Bioceres S.A.. See Note 2.4.

|                             |     | June 30, 
     2024 |     | June 30, 
     2023 |
|:----------------------------|:----|---------:|:----|---------:|
| Trade and other receivables |     |    3,501 |     |    3,536 |

Transactions with Bioceres S.A. were as follows:

|